On August 12, 2015 Endocyte, Inc. (NASDAQ:ECYT), a bio-pharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, reported that six posters will be presented by Endocyte scientists at the 250th American Chemical Society (ACS) National Meeting & Exposition being held in Boston, August 16-20, 2015 (Press release, Endocyte, AUG 12, 2015, View Source [SID:1234507221]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Endocyte’s versatile technology platform for developing SMDCs toward folate-receptor-specific and prostate-specific-membrane-antigen-specific targeting will be highlighted at the national ACS meeting," said Iontcho Vlahov, Ph.D., vice president of discovery chemistry. "The focus of our presentations is centered on novel chemistries for targeted therapies of cancer, including cytotoxic GARFTase inhibitors, CCK2R-targeting conjugates, and our continued advancement in the design of super-potent analogs of the tubulysin. We will further discuss new folate conjugates and their properties."

Presentations are as follows:

Abstract #: MEDI 162
Title: "Novel strategies for targeted therapies of cancer: Solid-phase-based synthesis of CCK-2-receptor-targeting ligands and their tubulysin conjugates"
When: Sunday, August 16, 2015 from 7 – 9 p.m. EDT
Session ID: General Poster Session
Location: Westin Boston Waterfront, Galleria

Abstract #: MEDI 205
Title: "Design and regio-selective synthesis of folate-thapsigargin conjugates for cancer therapy"
When: Sunday, August 16, 2015 from 7 – 9 p.m. EDT
Session ID: General Poster Session
Location: Westin Boston Waterfront, Galleria

Abstract #: MEDI 497
Title: "Chemistry of folate-everolimus and folate-rapamycin conjugates: Avoiding side reactions and improving their physical properties"
When: Wednesday, August 19, 2015 from 7 – 9 p.m. EDT
Session ID: General Poster Session
Location: Boston Convention & Exhibition Center, Ballroom

Abstract #: MEDI 499
Title: "Novel strategies for targeted therapies of cancer: Double release mechanism for delivering cytotoxic GARFTase inhibitors and additional chemotherapeutic payloads to cancer cells"
When: Wednesday, August 19, 2015 from 7 – 9 p.m. EDT
Session ID: General Poster Session
Location: Boston Convention & Exhibition Center, Ballroom

Abstract #: MEDI 516
Title: "Design and synthesis of novel tubulysin analogs"
When: Wednesday, August 19, 2015 from 7 – 9 p.m. EDT
Session ID: General Poster Session
Location: Boston Convention & Exhibition Center, Ballroom

Abstract #: MEDI 517
Title: "Reducing off-target activity of folate-tubulysin conjugates by introducing unnatural amino acids and by increasing steric bulk within the peptidic spacer"
When: Wednesday, August 19, 2015 from 7 – 9 p.m. EDT
Session ID: General Poster Session
Location: Boston Convention & Exhibition Center, Ballroom